PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 33, issue 12, 2015

Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs? pp. 1241-1244

Livio Garattini, Francesca Ghislandi and Milene Costa

Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease pp. 1245-1253

Zobair Younossi and Linda Henry

Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice pp. 1255-1268

James O’Mahony, Anthony Newall and Joost Rosmalen

Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence pp. 1269-1279

Christina Giannopoulou, Eleftherios Sideris, Ros Wade, Thirimon Moe-Byrne, Alison Eastwood and Claire McKenna

Cost-Value Analysis and the SAVE: A Work in Progress, But an Option for Localised Decision Making? pp. 1281-1288

Jonathan Karnon and Andrew Partington

Valuing QALYs in Relation to Equity Considerations Using a Discrete Choice Experiment pp. 1289-1300

Liesbet Wetering, Job van Exel, Ana Bobinac and Werner Brouwer

Cost Effectiveness of Falls and Injury Prevention Strategies for Older Adults Living in Residential Aged Care Facilities pp. 1301-1310

Jody Church, Marion Haas and Stephen Goodall

Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland pp. 1311-1324

Florian Gutzwiller, Alena Pfeil, Zanfina Ademi, Patricia Blank, Peter Braunhofer, Thomas Szucs and Matthias Schwenkglenks

Volume 33, issue 11, 2015

Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values? pp. 1101-1105

Tessa Peasgood and John Brazier

Assessing the Economics of Dengue: Results from a Systematic Review of the Literature and Expert Survey pp. 1107-1135

Dagna Constenla, Cristina Garcia and Noah Lefcourt

Can The EQ-5D Detect Meaningful Change? A Systematic Review pp. 1137-1154

Nalin Payakachat, Mir Ali and J. Tilford

Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review pp. 1155-1185

Insiya Poonawalla, Rohan Parikh, Xianglin Du, Helena VonVille and David Lairson

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective pp. 1187-1194

Emma Simpson, Sarah Davis, Praveen Thokala, Penny Breeze, Peter Bryden and Ruth Wong

Evaluating the Generalisability of Trial Results: Introducing a Centre- and Trial-Level Generalisability Index pp. 1195-1214

Adrian Gheorghe, Tracy Roberts, Karla Hemming and Melanie Calvert

Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany pp. 1215-1228

Katharina Schremser, Wolf Rogowski, Sigrid Adler-Reichel, Amanda Tufman, Rudolf Huber and Björn Stollenwerk

Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness pp. 1229-1236

Mikael Svensson, Fredrik Nilsson and Karl Arnberg

Volume 33, issue 10, 2015

Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement pp. 985-991

Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, Louise Longworth, Mark Oppe, Robert Froud and Alastair Gray

The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration pp. 993-1011

Stavros Petrou, Oliver Rivero-Arias, Helen Dakin, Louise Longworth, Mark Oppe, Robert Froud and Alastair Gray

A Review of the Development and Application of Generic Multi-Attribute Utility Instruments for Paediatric Populations pp. 1013-1028

Gang Chen and Julie Ratcliffe

A Systematic Review of the Economic and Humanistic Burden of Gout pp. 1029-1047

Gemma Shields and Stephen Beard

Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment pp. 1049-1067

Gregory Kruse, Bruce Wong, Mei Duh, Patrick Lefebvre, Marie-Hélène Lafeuille and John Fastenau

Pre-eclampsia Diagnosis and Treatment Options: A Review of Published Economic Assessments pp. 1069-1082

Neily Zakiyah, Maarten Postma, Philip Baker and Antoinette Asselt

Adjusting for Baseline Covariates in Net Benefit Regression: How You Adjust Matters pp. 1083-1090

Wanrudee Isaranuwatchai, Maureen Markle-Reid and Jeffrey Hoch

Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke pp. 1091-1100

Nobuyoshi Takabayashi, Kyoko Murata, Shiro Tanaka and Koji Kawakami

Volume 33, issue 9, 2015

Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation pp. 887-892

Scott Nelson, Daniel Malone and Joanne Lafleur

Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective pp. 893-904

Nigel Fleeman, Adrian Bagust, Sophie Beale, Angela Boland, Rumona Dickson, Kerry Dwan, Marty Richardson, Yenal Dundar, Helen Davis and Lindsay Banks

Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review pp. 905-924

Bonny Parkinson, Catherine Sermet, Fiona Clement, Steffan Crausaz, Brian Godman, Sarah Garner, Moni Choudhury, Sallie-Anne Pearson, Rosalie Viney, Ruth Lopert and Adam Elshaug

The Economic and Humanistic Burden of Severe Sepsis pp. 925-937

Bogdan Tiru, Ernest DiNino, Abigail Orenstein, Patrick Mailloux, Adam Pesaturo, Abhinav Gupta and William McGee

Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review pp. 939-955

Yoko Laurence, Ulla Griffiths and Anna Vassall

Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia pp. 957-965

Sabina Sanghera, Emma Frew, Janesh Gupta, Joe Kai and Tracy Roberts

A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark pp. 967-979

Anne Vestergaard and Lars Ehlers

Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy” pp. 981-982

Afschin Gandjour

The Authors’ Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy” pp. 983-983

Janneke Grutters, Marjolein Asselt, Kalipso Chalkidou and Manuela Joore

Volume 33, issue 8, 2015

Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions pp. 777-781

Gerardus Frederix, Hossein Haji Ali Afzali, Erik Dasbach and Robyn Ward

Cost Effectiveness of Preventive Treatment for Tuberculosis in Special High-Risk Populations pp. 783-809

Roland Diel, Niklas Lampenius and Albert Nienhaus

The Economic Costs of Type 2 Diabetes: A Global Systematic Review pp. 811-831

Till Seuring, Olga Archangelidi and Marc Suhrcke

Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 833-847

Matt Stevenson, Abdullah Pandor, John Stevens, Andrew Rawdin, Peter Rice, Jez Thompson and Marsha Morgan

Choice of Outcome Measure in an Economic Evaluation: A Potential Role for the Capability Approach pp. 849-855

Paula Lorgelly

Characterizing Heterogeneity Bias in Cohort-Based Models pp. 857-865

Elamin Elbasha and Jagpreet Chhatwal

A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE) pp. 867-877

Feng Xie, A. Pickard, Paul Krabbe, Dennis Revicki, Rosalie Viney, Nancy Devlin and David Feeny

Does it Matter Whether Canada’s Separate Health Technology Assessment Process for Cancer Drugs has an Economic Rationale? pp. 879-882

Jeffrey Hoch, Jaclyn Beca, Mona Sabharwal, Scott Livingstone and Anthony Fields

The Silence in Hoch et al.’s Commentary about the Rationale for and Objective(s) of Canada’s Separate HTA Process for Cancer Drugs: The Importance of Transparency and Accountability when Allocating Taxpayers’ Dollars pp. 883-886

Heather McDonald, Cathy Charles, Laurie Elit and Amiram Gafni

Volume 33, issue 7, 2015

For a Step Change to Curb the Obesity Epidemic pp. 613-617

Christian Frois and Pierre-Yves Cremieux

Policy Makers’ Views of Obesity-Related Challenges Around the World pp. 619-628

Pierre Cremieux

Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications pp. 629-641

Amarpreet Chawla, Chia-Wen Hsiao, Martha Romney, Ricardo Cohen, Francesco Rubino, Philip Schauer and Pierre Cremieux

The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA pp. 643-653

Charles Baum, Katherine Andino, Eric Wittbrodt, Shelley Stewart, Keith Szymanski and Robin Turpin

Obesity in the Context of Aging: Quality of Life Considerations pp. 655-672

Francesco Corica, Giampaolo Bianchi, Andrea Corsonello, Natalia Mazzella, Fabrizia Lattanzio and Giulio Marchesini

The Epidemiology of Obesity: A Big Picture pp. 673-689

Adela Hruby and Frank Hu

The Effect of Obesity and Chronic Conditions on Medicare Spending, 1987–2011 pp. 691-697

Lindsay Allen, Ken Thorpe and Peter Joski

Cost-Effectiveness Analysis of Qsymia for Weight Loss pp. 699-706

Eric Finkelstein, Eliza Kruger and Sunil Karnawat

Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status pp. 707-722

John Cawley, Chad Meyerhoefer, Adam Biener, Mette Hammer and Neil Wintfeld

Do Statins Reduce the Health and Health Care Costs of Obesity? pp. 723-734

Etienne Gaudette, Dana Goldman, Andrew Messali and Neeraj Sood

The Economic Burden of Obesity by Glycemic Stage in the United States pp. 735-748

Qian Li, Steven Blume, Joanna Huang, Mette Hammer and Thomas Graf

The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation pp. 749-763

Anita Chawla, Ginger Carls, Edmund Deng and Edward Tuttle

Preventing Obesity in the USA: Impact on Health Service Utilization and Costs pp. 765-776

Michele Cecchini and Franco Sassi

Volume 33, issue 6, 2015

Simulation and Matching-Based Approaches for Indirect Comparison of Treatments pp. 537-549

K. Ishak, Irina Proskorovsky and Agnes Benedict

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry pp. 551-560

Hedwig Blommestein, Margreet Franken and Carin Uyl- de Groot

Pharmacological Management of Chronic Lower Back Pain: A Review of Cost Effectiveness pp. 561-569

Marion Haas and Richard Abreu Lourenco

Welfarism Versus Extra-Welfarism: Can the Choice of Economic Evaluation Approach Impact on the Adoption Decisions Recommended by Economic Evaluation Studies? pp. 571-579

James Buchanan and Sarah Wordsworth

Cost Effectiveness of Dipeptidyl Peptidase-4 Inhibitors for Type 2 Diabetes pp. 581-597

Jinsong Geng, Hao Yu, Yiwei Mao, Peng Zhang and Yingyao Chen

Cost-Utility Analysis of a Medication Review with Follow-Up Service for Older Adults with Polypharmacy in Community Pharmacies in Spain: The conSIGUE Program pp. 599-610

Francisco Jódar-Sánchez, Amaia Malet-Larrea, José Martín, Leticia García-Mochón, M. López del Amo, Fernando Martínez-Martínez, Miguel Gastelurrutia-Garralda, Victoria García-Cárdenas, Daniel Sabater-Hernández, Loreto Sáez-Benito and Shalom Benrimoj

Erratum to: Cost Effectiveness of Oromucosal Cannabis-Based Medicine (Sativex ® ) for Spasticity in Multiple Sclerosis pp. 611-611

Lanting Lu, Hilary Pearce, Chris Roome, James Shearer, Iain Lang and Ken Stein

Volume 33, issue 5, 2015

Economic Evaluations with Agent-Based Modelling: An Introduction pp. 423-433

Jagpreet Chhatwal and Tianhua He

Exploring Structural Uncertainty in Model-Based Economic Evaluations pp. 435-443

Hossein Haji Ali Afzali and Jonathan Karnon

A Review and Classification of Approaches for Dealing with Uncertainty in Multi-Criteria Decision Analysis for Healthcare Decisions pp. 445-455

Henk Broekhuizen, Catharina Groothuis-Oudshoorn, Janine Til, J. Hummel and Maarten IJzerman

The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence pp. 457-466

Ros Wade, Ana Duarte, Mark Simmonds, Rocio Rodriguez-Lopez, Steven Duffy, Nerys Woolacott and Eldon Spackman

Systematic Review of Humanistic and Economic Burden of Symptomatic Chronic Obstructive Pulmonary Disease pp. 467-488

Kunal Srivastava, Deepika Thakur, Sheetal Sharma and Yogesh Punekar

Probabilistic Markov Model Estimating Cost Effectiveness of Methylphenidate Osmotic-Release Oral System Versus Immediate-Release Methylphenidate in Children and Adolescents: Which Information is Needed? pp. 489-509

Saskia Schawo, Annemarie Kolk, Clazien Bouwmans, Lieven Annemans, Maarten Postma, Jan Buitelaar, Michel Agthoven and Leona Hakkaart- van Roijen

Cost of Acute Stroke Care for Patients with Atrial Fibrillation Compared with Those in Sinus Rhythm pp. 511-520

Ali Ali, Joanne Howe and Ahmed Abdel-Hafiz

Cost-Utility Analysis of Intravenous Immunoglobulin for the Treatment of Steroid-Refractory Dermatomyositis in Thailand pp. 521-531

Naruemon Bamrungsawad, Nathorn Chaiyakunapruk, Nilawan Upakdee, Chayanin Pratoomsoot, Rosarin Sruamsiri and Piyameth Dilokthornsakul

Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis pp. 533-534

Sabina Sanghera, Emma Frew and Tracy Roberts

Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration pp. 535-536

Don Husereau, Michael Drummond, Stavros Petrou, Dan Greenberg, Josephine Mauskopf, Federico Augustovski, Andrew Briggs, David Moher, Elizabeth Loder and Chris Carswell

Volume 33, issue 4, 2015

Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant Staphylococcus aureus pp. 285-325

Fernando Antonanzas, Carmen Lozano and Carmen Torres

Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis pp. 327-340

Wei Zhang, Nazrul Islam, Canice Ma and Aslam Anis

Cost-of-Illness Studies for Bipolar Disorder: Systematic Review of International Studies pp. 341-353

Huajie Jin and Paul McCrone

An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis pp. 355-366

Rachael Hunter, Gianluca Baio, Thomas Butt, Stephen Morris, Jeff Round and Nick Freemantle

Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada pp. 367-380

Thomas Delea, Jordan Amdahl, Alice Wang, Mayur Amonkar and Marroon Thabane

Cost-Effectiveness Analysis of OnabotulinumtoxinA (BOTOX ® ) for the Management of Urinary Incontinence in Adults with Neurogenic Detrusor Overactivity: A UK Perspective pp. 381-393

Rizwan Hamid, Clara Loveman, Jim Millen, Denise Globe, Catherine Corbell, Danielle Colayco, Sanja Stanisic and Dmitry Gultyaev

Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control pp. 395-408

Andrej Janzic and Mitja Kos

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy pp. 409-422

Essè Akpo, Karin Cerri and Joris Kleintjens

Volume 33, issue 3, 2015

Is it Time to Update Societal Value Sets for Preference-Based Measures of Health? pp. 191-192

A. Pickard

Resource Modelling: The Missing Piece of the HTA Jigsaw? pp. 193-203

Praveen Thokala, Simon Dixon and Beate Jahn

A Systematic Review of Cost-Effectiveness Analyses of Drugs for Postmenopausal Osteoporosis pp. 205-224

Mickaël Hiligsmann, Silvia Evers, Wafa Ben Sedrine, John Kanis, Bram Ramaekers, Jean-Yves Reginster, Stuart Silverman, Caroline Wyers and Annelies Boonen

Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective pp. 225-233

Michael Holmes, Sarah Davis and Emma Simpson

Is There an Economic Rationale for Cancer Drugs to Have a Separate Reimbursement Review Process for Resource Allocation Purposes? pp. 235-241

Heather McDonald, Cathy Charles, Laurie Elit and Amiram Gafni

Costs of Health Resource Utilization Among HIV-Positive Individuals in British Columbia, Canada: Results From a Population-Level Study pp. 243-253

Bohdan Nosyk, Viviane Lima, Guillaume Colley, Benita Yip, Robert Hogg and Julio Montaner

Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework pp. 255-269

Mike Paulden, Tania Stafinski, Devidas Menon and Christopher McCabe

Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation pp. 271-283

Alexander Mensch, Stephanie Stock, Björn Stollenwerk and Dirk Müller

Volume 33, issue 2, 2015

Are We Lacking Economic Evaluations in Gastric Cancer Treatment? pp. 83-87

Alyson Mahar, Abraham El-Sedfy, Savtaj Brar, Ana Johnson and Natalie Coburn

Cost-Value Analysis of Health Interventions: Introduction and Update on Methods and Preference Data pp. 89-95

Erik Nord

A Primer on Marginal Effects—Part II: Health Services Research Applications pp. 97-103

E. Onukwugha, Jason Bergtold and R. Jain

A Practical Guide to Value of Information Analysis pp. 105-121

Edward Wilson

Does Including Informal Care in Economic Evaluations Matter? A Systematic Review of Inclusion and Impact of Informal Care in Cost-Effectiveness Studies pp. 123-135

Marieke Krol, Jocé Papenburg and Job van Exel

Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal pp. 137-148

Janette Greenhalgh, Adrian Bagust, Angela Boland, James Oyee, Nicola Trevor, Sophie Beale, Yenal Dundar, Juliet Hockenhull, Chris Proudlove and Susan O’Reilly

Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK pp. 149-161

P. McEwan, H. Bennett, Tyler Ward and K. Bergenheim

Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis pp. 163-177

Laura Sawyer, David Wonderling, Karina Jackson, Ruth Murphy, Eleanor Samarasekera and Catherine Smith

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients pp. 179-190

Patricia Blank, Martin Filipits, Peter Dubsky, Florian Gutzwiller, Michael Lux, Jan Brase, Karsten Weber, Margaretha Rudas, Richard Greil, Sibylle Loibl, Thomas Szucs, Ralf Kronenwett, Matthias Schwenkglenks and Michael Gnant

Volume 33, issue 1, 2015

Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy pp. 1-4

Janneke Grutters, Marjolein Asselt, Kalipso Chalkidou and Manuela Joore

Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods pp. 5-11

Sebastian Hinde and Eldon Spackman

Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer pp. 13-23

Nigel Fleeman, Adrian Bagust, Sophie Beale, Kerry Dwan, Rumona Dickson, Chris Proudlove and Yenal Dundar

A Primer on Marginal Effects—Part I: Theory and Formulae pp. 25-30

Eberechukwu Onukwugha, Jason Bergtold and Rahul Jain

Estimating Productivity Costs in Health Economic Evaluations: A Review of Instruments and Psychometric Evidence pp. 31-48

Kenneth Tang

Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation pp. 49-59

Wolf Rogowski, Katherine Payne, Petra Schnell-Inderst, Andrea Manca, Ursula Rochau, Beate Jahn, Oguzhan Alagoz, Reiner Leidl and Uwe Siebert

Validation of the Underlying Assumptions of the Quality-Adjusted Life-Years Outcome: Results from the ECHOUTCOME European Project pp. 61-69

Ariel Beresniak, Antonieta Medina-Lara, Jean Auray, Alain Wever, Jean-Claude Praet, Rosanna Tarricone, Aleksandra Torbica, Danielle Dupont, Michel Lamure and Gerard Duru

Reduce Mortality Risk Above All Else: A Discrete-Choice Experiment in Acute Coronary Syndrome Patients pp. 71-81

Axel Mühlbacher and Susanne Bethge